Global Antifungal Drugs Market: Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others), By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, China, Japan, India)
Executive Summary
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Antifungal Drugs Market. The report analyses the Antifungal Drugs Market By Drug Type (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others). The report analyses the Antifungal Drugs Market, By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, Germany, U.K, France, China, Japan, India) for the historical period of 2013-2017 and the forecast period of 2018-2023.
According to Azoth Analytics research report “Global Antifungal Drugs Market: Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others), By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, China, Japan, India)”, the antifungal drugs market is projected to display a robust growth represented by a CAGR of 3.70% during 2018 – 2023.
Over the recent years, Antifungal Drugs market has been witnessing growth on account of several driving factors including growing prevalence of fungal infections such as candidiasis and aspergillosis, increasing popularity of over-the-counter drugs, and increase in availability of innovative antifungals. Moreover, increasing awareness regarding fatal antifungal diseases, growing medical spending, favorable government initiatives, public private partnership have been driving the market growth. In addition, rising geriatric population, increasing global healthcare expenditure and technological advancements in pharmaceuticals research, growing scope in developing countries with large population such as China and India is anticipated to impel the market growth of the antifungal drugs market. However, growing portfolio of antifungal generic drugs, patent expiration of innovator drugs, increasing prevalence of fungal resistance, and counterfeit drugs are expected to hinder the market performance during forecasted period.
In this research report, the market is segmented on the basis of drug class and therapeutic indications. By drug class, the azoles class antifungals are predicted to hold their dominant position in the market. By therapeutic indications, drugs use in the treatment of candidiasis are anticipated to creates their dominance in global antifungal drugs market. Amongst the regions, North America accounts for the largest regional share in the global antifungal drugs market in 2017. The largest share of North America is attributed to presence of enormous number of patient base and highly advanced medical infrastructure.
The report titled “Global Antifungal Drugs Market: Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others), By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, China, Japan, India)”, has covered and analysed the potential of antifungal drugs market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the antifungal drugs. Additionally, the report also highlights market entry strategies for various companies across the globe.
Scope of the Report
Global Antifungal Drugs Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Antifungal Drugs Market. The report analyses the Antifungal Drugs Market By Drug Type (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others). The report analyses the Antifungal Drugs Market, By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, Germany, U.K, France, China, Japan, India) for the historical period of 2013-2017 and the forecast period of 2018-2023.
According to Azoth Analytics research report “Global Antifungal Drugs Market: Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others), By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, China, Japan, India)”, the antifungal drugs market is projected to display a robust growth represented by a CAGR of 3.70% during 2018 – 2023.
Over the recent years, Antifungal Drugs market has been witnessing growth on account of several driving factors including growing prevalence of fungal infections such as candidiasis and aspergillosis, increasing popularity of over-the-counter drugs, and increase in availability of innovative antifungals. Moreover, increasing awareness regarding fatal antifungal diseases, growing medical spending, favorable government initiatives, public private partnership have been driving the market growth. In addition, rising geriatric population, increasing global healthcare expenditure and technological advancements in pharmaceuticals research, growing scope in developing countries with large population such as China and India is anticipated to impel the market growth of the antifungal drugs market. However, growing portfolio of antifungal generic drugs, patent expiration of innovator drugs, increasing prevalence of fungal resistance, and counterfeit drugs are expected to hinder the market performance during forecasted period.
In this research report, the market is segmented on the basis of drug class and therapeutic indications. By drug class, the azoles class antifungals are predicted to hold their dominant position in the market. By therapeutic indications, drugs use in the treatment of candidiasis are anticipated to creates their dominance in global antifungal drugs market. Amongst the regions, North America accounts for the largest regional share in the global antifungal drugs market in 2017. The largest share of North America is attributed to presence of enormous number of patient base and highly advanced medical infrastructure.
The report titled “Global Antifungal Drugs Market: Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others), By Region, By Country (2019 Edition): Opportunities and Forecast (2013-2023) - By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, China, Japan, India)”, has covered and analysed the potential of antifungal drugs market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the antifungal drugs. Additionally, the report also highlights market entry strategies for various companies across the globe.
Scope of the Report
Global Antifungal Drugs Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)
- Antifungal Drugs Market– Size, Growth, Forecast
- Analysis By Drug Type - Azole Class Antifungal Drugs, Echinocandins Class Antifungal Drugs, Polyenes Class Antifungal Drugs, Other Class Antifungal Drugs
- Analysis By Therapeutic Indications - Aspergillus, Dermatophytosis, Candidiasis, Other Therapeutic Indications
- Antifungal Drugs Market– Size, Growth, Forecast
- Analysis By Drug Type - Azole Class Antifungal Drugs, Echinocandins Class Antifungal Drugs, Polyenes Class Antifungal Drugs, Other Class Antifungal Drugs
- Analysis By Therapeutic Indications - Aspergillus, Dermatophytosis, Candidiasis, Other Therapeutic Indications
- Antifungal Drugs Market– Size, Growth, Forecast
- Analysis By Drug Type - Azole Class Antifungal Drugs, Echinocandins Class Antifungal Drugs, Polyenes Class Antifungal Drugs, Other Class Antifungal Drugs
- Analysis By Therapeutic Indications - Aspergillus, Dermatophytosis, Candidiasis, Other Therapeutic Indications
- Market Dynamics – Drivers and Restraints.
- Market Trends.
- Porter Five Forces Analysis.
- SWOT Analysis.
- Company Analysis - Merck & Co., Glaxo Smith Kline, Astellas Pharma, Sanofi, Abbott Laboratories, Bayer, Kramer Laboratories, Novartis International AG, Pfizer.
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
1. RESEARCH METHODOLOGY
2. EXECUTIVE SUMMARY
3. STRATEGIC RECOMMENDATIONS
4. ANTIFUNGAL DRUGS PRODUCTS OUTLOOK
5. GLOBAL ANTIFUNGAL DRUGS MARKET: GROWTH AND FORECAST
5.1 By Value (2013-2017)
5.2 By Value (2018-2023)
6. GLOBAL ANTIFUNGAL DRUGS MARKET: SEGMENTAL ANALYSIS
6.1 Global Antifungal Drugs Market Size, By Drug Class: Breakdown (%)
6.1.1 Global Antifungal Drugs Market Size, By Drug Class, 2017 (%)
6.1.2 Global Antifungal Drugs Market Size, By Drug Class, 2023 (%)
6.2 Global Azole Class Antifungal Drugs Market Size, By Value (2013-2023)
6.3 Global Echinocandins Class Antifungal Drugs Market Size, By Value (2013-2023)
6.4 Global Polyenes Antifungal Drugs Market Size, By Value (2013-2023)
6.5 Global Other Antifungal Drugs Market Size, By Value (2013-2023)
6.6 Global Antifungal Drugs: Market Attractiveness, By Drug Class
6.7 Global Antifungal Drugs Market Size, By Therapeutic Indications: Breakdown(%)
6.7.1 Global Aspergillus Antifungal Drugs Market Size, By Value (2013-2023)
6.7.2 Global Dermatophytosis Antifungal Drugs Market Size, By Value (2013-2023)
6.7.3 Global Candidiasis Antifungal Drugs Market Size, By Value (2013-2023)
6.6.2 Global Other Therapeutic Indications Antifungal Drugs Market Size, By Value (2013-2023)
7. GLOBAL ANTIFUNGAL DRUGS MARKET: REGIONAL ANALYSIS
7.1 Global Antifungal Drugs Market Size, By Region: Breakdown (%)
7.1.1 Global Antifungal Drugs Market Size, By Region, 2017 (%)
7.1.2 Global Antifungal Drugs Market Size, By Region, 2023 (%)
8. NORTH AMERICA ANTIFUNGAL DRUGS MARKET: AN ANALYSIS
8.1 North America Antifungal Drugs Market: Segment Analysis
8.2 North America Antifungal Drugs Market Size, By Drug Class: Breakdown (%)
8.2.1 North America Antifungal Drugs Market Size, By Drug Class, 2017 (%)
8.2.2 North America Antifungal Drugs Market Size, By Drug Class, 2023 (%)
8.3 North America Azoles Antifungal Drugs Market Size, By Value (2013-2023)
8.4 North America Echinocandins Antifungal Drugs Market Size, By Value (2013-2023)
8.5 North America Polyenes Antifungal Drugs Market Size, By Value (2013-2023)
8.6 North America Others Antifungal Drugs Market Size, By Value (2013-2023)
8.7 North America Antifungal Drugs Market Size, By Therapeutic Indications: Breakdown(%)
8.7.1 North America Aspergillus Antifungal Drugs Size, By Value (2013-2023)
8.7.2 North America Dermatophytosis Antifungal Drugs Market Size, By Value (2013-2023)
8.7.3 North America Candidiasis Antifungal Drugs Size, By Value (2013-2023)
8.7.4 North America Other Therapeutic Indications Antifungal Drugs Market Size, By Value (2013-2023)
8.8 North America Antifungal Drugs Market: Country Analysis (U.S and Canada)
8.8.1 U.S Antifungal Drugs Market, By Value (2013-2023)
8.8.2 U.S Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
8.8.3 U.S Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
8.8.4 Canada Antifungal Drugs Market, By Value (2013-2023)
8.8.5 Canada Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
8.8.6 Canada Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
9. EUROPE ANTIFUNGAL DRUGS MARKET: AN ANALYSIS
9.1 Europe Antifungal Drugs Market: Segmental Analysis
9.2 Europe Antifungal Drugs Market Size, By Drug Class: Breakdown (%)
9.1.2 Europe Antifungal Drugs Market Size, By Drug Class, 2017 (%)
9.1.3 Europe Antifungal Drugs Market Size, By Drug Class, 2023 (%)
9.3 Europe Azoles Antifungal Drugs Market Size, By Value (2013-2023)
9.4 Europe Echinocandins Drugs Market Size, By Value (2013-2023)
9.5 Europe Polyenes Antifungal Drugs Market Size, By Value (2013-2023)
9.6 Europe Antifungal Drugs Market Size, By Therapeutic Indications: Breakdown(%)
9.6.1 Europe Aspergillosis Antifungal Drugs Market Size, By Value (2013-2023)
9.6.2 Europe Dermatophytosis Antifungal Drugs Market Size, By Value (2013-2023)
9.6.3 Europe Candidiasis Antifungal Drugs Market Size, By Value (2013-2023)
9.6.4 Europe Other Therapeutic Indications Antifungal Drugs Market Size, By Value (2013-2023)
9.7 Europe Antifungal Drugs Market: Country Analysis (Germany, France, Italy, U.K)
9.7.1 Germany Antifungal Drugs Market, By Value (2013-2023)
9.7.2 Germany Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
9.7.3 Germany Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
9.7.4 France Antifungal Drugs Market, By Value (2013-2023)
9.7.5 France Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
9.7.6 France Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
9.7.7 UK Antifungal Drugs Market, By Value (2013-2023)
9.7.8 UK Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
9.7.9 UK Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
10. APAC ANTIFUNGAL DRUGS MARKET: AN ANALYSIS
10.1 APAC Antifungal Drugs Market: Segmental Analysis
10.2 APAC Antifungal Drugs Market Size, By Drug Class: Breakdown (%)
10.2.1 APAC Antifungal Drugs Market Size, By Drug Class, 2017 (%)
10.2.2 APAC Antifungal Drugs Market Size, By Drug Class, 2023 (%)
10.3 APAC Azole Antifungal Drugs Market Size, By Value (2013-2023)
10.4 APAC Echinocandins Antifungal Drugs Market Size, By Value (2013-2023)
10.5 APAC Polyenes Antifungal Drugs Market Size, By Value (2013-2023)
10.6 APAC Other Antifungal Drugs Market Size, By Value (2013-2023)
10.7 APAC Antifungal Drugs Market Size, By Therapeutic Indications: Breakdown(%)
10.7.1 APAC Aspergillosis Antifungal Drugs Market Size, By Value (2013-2023)
10.7.2 APAC Dermatophytosis Antifungal Drugs Market Size, By Value (2013-2023)
10.7.3 APAC Candidiasis Antifungal Drugs Market Size, By Value (2013-2023)
10.7.4 APAC Other Therapeutic Indications Antifungal Drugs Market Size, By Value (2013-2023)
10.8 APAC Antifungal Drugs Market: Country Analysis (China, Japan, and India)
10.8.1 China Antifungal Drugs Market, By Value (2013-2023)
10.8.2 China Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
10.8.3 China Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
10.8.4 Japan Antifungal Drugs Market, By Value (2013-2023)
10.8.5 Japan Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
10.8.6 Japan Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
10.8.7 India Antifungal Drugs Market, By Value (2013-2023)
10.8.8 India Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
10.8.9 India Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
11. ROW ANTIFUNGAL DRUGS MARKET: GROWTH AND FORECAST
11.1 ROW Antifungal Drugs Market: Segmental Analysis
11.2 ROW Antifungal Drugs Market Size, By Drug Class: Breakdown (%)
11.1.1 ROW Antifungal Drugs Market Size, By Drug Class, 2017 (%)
11.1.2 ROW Antifungal Drugs Market Size, By Drug Class, 2023 (%)
11.3 ROW Azole Antifungal Drugs Market Size, By Value (2013-2023)
11.4 ROW Echinocandins Antifungal Drugs Market Size, By Value (2013-2023)
11.5 ROW Polyenes Antifungal Drugs Market Size, By Value (2013-2023)
11.6 ROW Other Antifungal Drugs Market Size, By Value (2013-2023)
11.7 ROW Antifungal Drugs Market Size, By Therapeutic Indications: Breakdown(%)
11.7.1 ROW Aspergillosis Antifungal Drugs Market Size, By Value (2013-2023)
11.7.2 ROW Dermatophytosis Antifungal Drugs Market Size, By Value (2013-2023)
11.7.3 ROW Candidiasis Antifungal Drugs Market Size, By Value (2013-2023)
11.7.4 ROW Other Therapeutic Indications Antifungal Drugs Market Size, By Value (2013-2023)
12. GLOBAL ANTIFUNGAL DRUGS MARKET: MARKET DYNAMICS
12.1 Global Antifungal Drugs Market Drivers
12.2 Global Antifungal Drugs Market Restrains
12.3 Global Antifungal Drugs Market Trends
13. PORTER FIVE FORCE ANALYSIS
14. SWOT ANALYSIS
15. ANTIFUNGAL DRUGS MARKET – COMPETITIVE LANDSCAPE
16. COMPANY PROFILES
16.1 Merck & Co.
16.2 Pfizer
16.3 GSK
16.4 Novartis
16.5 Abbott Laboratories
16.6 Astellas Pharma
16.7 Bayer
16.8 Sanofi
16.9 Kramer Laboratories
2. EXECUTIVE SUMMARY
3. STRATEGIC RECOMMENDATIONS
4. ANTIFUNGAL DRUGS PRODUCTS OUTLOOK
5. GLOBAL ANTIFUNGAL DRUGS MARKET: GROWTH AND FORECAST
5.1 By Value (2013-2017)
5.2 By Value (2018-2023)
6. GLOBAL ANTIFUNGAL DRUGS MARKET: SEGMENTAL ANALYSIS
6.1 Global Antifungal Drugs Market Size, By Drug Class: Breakdown (%)
6.1.1 Global Antifungal Drugs Market Size, By Drug Class, 2017 (%)
6.1.2 Global Antifungal Drugs Market Size, By Drug Class, 2023 (%)
6.2 Global Azole Class Antifungal Drugs Market Size, By Value (2013-2023)
6.3 Global Echinocandins Class Antifungal Drugs Market Size, By Value (2013-2023)
6.4 Global Polyenes Antifungal Drugs Market Size, By Value (2013-2023)
6.5 Global Other Antifungal Drugs Market Size, By Value (2013-2023)
6.6 Global Antifungal Drugs: Market Attractiveness, By Drug Class
6.7 Global Antifungal Drugs Market Size, By Therapeutic Indications: Breakdown(%)
6.7.1 Global Aspergillus Antifungal Drugs Market Size, By Value (2013-2023)
6.7.2 Global Dermatophytosis Antifungal Drugs Market Size, By Value (2013-2023)
6.7.3 Global Candidiasis Antifungal Drugs Market Size, By Value (2013-2023)
6.6.2 Global Other Therapeutic Indications Antifungal Drugs Market Size, By Value (2013-2023)
7. GLOBAL ANTIFUNGAL DRUGS MARKET: REGIONAL ANALYSIS
7.1 Global Antifungal Drugs Market Size, By Region: Breakdown (%)
7.1.1 Global Antifungal Drugs Market Size, By Region, 2017 (%)
7.1.2 Global Antifungal Drugs Market Size, By Region, 2023 (%)
8. NORTH AMERICA ANTIFUNGAL DRUGS MARKET: AN ANALYSIS
8.1 North America Antifungal Drugs Market: Segment Analysis
8.2 North America Antifungal Drugs Market Size, By Drug Class: Breakdown (%)
8.2.1 North America Antifungal Drugs Market Size, By Drug Class, 2017 (%)
8.2.2 North America Antifungal Drugs Market Size, By Drug Class, 2023 (%)
8.3 North America Azoles Antifungal Drugs Market Size, By Value (2013-2023)
8.4 North America Echinocandins Antifungal Drugs Market Size, By Value (2013-2023)
8.5 North America Polyenes Antifungal Drugs Market Size, By Value (2013-2023)
8.6 North America Others Antifungal Drugs Market Size, By Value (2013-2023)
8.7 North America Antifungal Drugs Market Size, By Therapeutic Indications: Breakdown(%)
8.7.1 North America Aspergillus Antifungal Drugs Size, By Value (2013-2023)
8.7.2 North America Dermatophytosis Antifungal Drugs Market Size, By Value (2013-2023)
8.7.3 North America Candidiasis Antifungal Drugs Size, By Value (2013-2023)
8.7.4 North America Other Therapeutic Indications Antifungal Drugs Market Size, By Value (2013-2023)
8.8 North America Antifungal Drugs Market: Country Analysis (U.S and Canada)
8.8.1 U.S Antifungal Drugs Market, By Value (2013-2023)
8.8.2 U.S Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
8.8.3 U.S Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
8.8.4 Canada Antifungal Drugs Market, By Value (2013-2023)
8.8.5 Canada Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
8.8.6 Canada Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
9. EUROPE ANTIFUNGAL DRUGS MARKET: AN ANALYSIS
9.1 Europe Antifungal Drugs Market: Segmental Analysis
9.2 Europe Antifungal Drugs Market Size, By Drug Class: Breakdown (%)
9.1.2 Europe Antifungal Drugs Market Size, By Drug Class, 2017 (%)
9.1.3 Europe Antifungal Drugs Market Size, By Drug Class, 2023 (%)
9.3 Europe Azoles Antifungal Drugs Market Size, By Value (2013-2023)
9.4 Europe Echinocandins Drugs Market Size, By Value (2013-2023)
9.5 Europe Polyenes Antifungal Drugs Market Size, By Value (2013-2023)
9.6 Europe Antifungal Drugs Market Size, By Therapeutic Indications: Breakdown(%)
9.6.1 Europe Aspergillosis Antifungal Drugs Market Size, By Value (2013-2023)
9.6.2 Europe Dermatophytosis Antifungal Drugs Market Size, By Value (2013-2023)
9.6.3 Europe Candidiasis Antifungal Drugs Market Size, By Value (2013-2023)
9.6.4 Europe Other Therapeutic Indications Antifungal Drugs Market Size, By Value (2013-2023)
9.7 Europe Antifungal Drugs Market: Country Analysis (Germany, France, Italy, U.K)
9.7.1 Germany Antifungal Drugs Market, By Value (2013-2023)
9.7.2 Germany Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
9.7.3 Germany Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
9.7.4 France Antifungal Drugs Market, By Value (2013-2023)
9.7.5 France Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
9.7.6 France Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
9.7.7 UK Antifungal Drugs Market, By Value (2013-2023)
9.7.8 UK Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
9.7.9 UK Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
10. APAC ANTIFUNGAL DRUGS MARKET: AN ANALYSIS
10.1 APAC Antifungal Drugs Market: Segmental Analysis
10.2 APAC Antifungal Drugs Market Size, By Drug Class: Breakdown (%)
10.2.1 APAC Antifungal Drugs Market Size, By Drug Class, 2017 (%)
10.2.2 APAC Antifungal Drugs Market Size, By Drug Class, 2023 (%)
10.3 APAC Azole Antifungal Drugs Market Size, By Value (2013-2023)
10.4 APAC Echinocandins Antifungal Drugs Market Size, By Value (2013-2023)
10.5 APAC Polyenes Antifungal Drugs Market Size, By Value (2013-2023)
10.6 APAC Other Antifungal Drugs Market Size, By Value (2013-2023)
10.7 APAC Antifungal Drugs Market Size, By Therapeutic Indications: Breakdown(%)
10.7.1 APAC Aspergillosis Antifungal Drugs Market Size, By Value (2013-2023)
10.7.2 APAC Dermatophytosis Antifungal Drugs Market Size, By Value (2013-2023)
10.7.3 APAC Candidiasis Antifungal Drugs Market Size, By Value (2013-2023)
10.7.4 APAC Other Therapeutic Indications Antifungal Drugs Market Size, By Value (2013-2023)
10.8 APAC Antifungal Drugs Market: Country Analysis (China, Japan, and India)
10.8.1 China Antifungal Drugs Market, By Value (2013-2023)
10.8.2 China Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
10.8.3 China Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
10.8.4 Japan Antifungal Drugs Market, By Value (2013-2023)
10.8.5 Japan Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
10.8.6 Japan Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
10.8.7 India Antifungal Drugs Market, By Value (2013-2023)
10.8.8 India Antifungal Drugs Market, By Drug Class, By Value (2013-2023)
10.8.9 India Antifungal Drugs Market, By Therapeutic Indications, By Value (2013-2023)
11. ROW ANTIFUNGAL DRUGS MARKET: GROWTH AND FORECAST
11.1 ROW Antifungal Drugs Market: Segmental Analysis
11.2 ROW Antifungal Drugs Market Size, By Drug Class: Breakdown (%)
11.1.1 ROW Antifungal Drugs Market Size, By Drug Class, 2017 (%)
11.1.2 ROW Antifungal Drugs Market Size, By Drug Class, 2023 (%)
11.3 ROW Azole Antifungal Drugs Market Size, By Value (2013-2023)
11.4 ROW Echinocandins Antifungal Drugs Market Size, By Value (2013-2023)
11.5 ROW Polyenes Antifungal Drugs Market Size, By Value (2013-2023)
11.6 ROW Other Antifungal Drugs Market Size, By Value (2013-2023)
11.7 ROW Antifungal Drugs Market Size, By Therapeutic Indications: Breakdown(%)
11.7.1 ROW Aspergillosis Antifungal Drugs Market Size, By Value (2013-2023)
11.7.2 ROW Dermatophytosis Antifungal Drugs Market Size, By Value (2013-2023)
11.7.3 ROW Candidiasis Antifungal Drugs Market Size, By Value (2013-2023)
11.7.4 ROW Other Therapeutic Indications Antifungal Drugs Market Size, By Value (2013-2023)
12. GLOBAL ANTIFUNGAL DRUGS MARKET: MARKET DYNAMICS
12.1 Global Antifungal Drugs Market Drivers
12.2 Global Antifungal Drugs Market Restrains
12.3 Global Antifungal Drugs Market Trends
13. PORTER FIVE FORCE ANALYSIS
14. SWOT ANALYSIS
15. ANTIFUNGAL DRUGS MARKET – COMPETITIVE LANDSCAPE
16. COMPANY PROFILES
16.1 Merck & Co.
16.2 Pfizer
16.3 GSK
16.4 Novartis
16.5 Abbott Laboratories
16.6 Astellas Pharma
16.7 Bayer
16.8 Sanofi
16.9 Kramer Laboratories
LIST OF FIGURES
Figure 1: Global Antifungal Drugs Market Size, By Value, 2013-2017 (USD Million)
Figure 2: Number of People Living With HIV, 2013-2017
Figure 3: Number of New Cases of Cancer, In 2018, By Type, (% of Total)
Figure 4: Estimated TB Incidences, By WHO Regions, 2016
Figure 5: Prevalence of Diagnosed Autoimmune Diseases, In 2018, By Selected Countries, (% of Total)
Figure 6: Burden of Antifungal Infections, By Type
Figure 7: Generic Market Value Share, In 2006 (Left) &2016 (Right), By Region
Figure 8: Global Prescription and OTC Drugs Sales, 2013-2017, (USD Billion)
Figure 9: Expected Global Medical Spending in 2020, By Product Type, (% of Total)
Figure 10: Expected Global Medical Spending in 2020, By Region, (% of Total)
Figure 11: Global Aged Population (Above 65), 2013-2017 (% of total)
Figure 12: Global Aged Population(Above 65), By Country, 2017 (% of total)
Figure 13: Healthcare Expenditure (Share of GDP), By Selected Country, 2013-2017 (In %)
Figure 14: GDP Per Capita PPP, By Region, 2018 (in Thousand USD)
Figure 15: Global Expected Healthcare Industry Outlook
Figure 16: Regional Expected Healthcare Industry Growth Rate By Year 2020
Figure 17: Global Antifungal Drugs Market Size, By Value, Forecast, 2018-2023 (USD Million)
Figure 18: Global Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 19: Global Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 20: Global Azoles Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 21: Global Azoles Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 22: Global Echinocandins Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 23: Global Echinocandins Antifungal Drugs Market, 2018-2023(USD Million)
Figure 24: Global Polyenes Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 25: Global Polyenes Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 26: Global Other Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 27: Global Other Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 28: Market Comparison Chart, By Product Type, 2013-2023 (USD Million)
Figure 29: Global Market Attractiveness, By Product Type, 2023F
Figure 30: Global Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 31: Global Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 32: Global Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 33: Global Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 34: Global Antifungal Drugs Market Size, By Region, 2017 (%)
Figure 35: Global Antifungal Drugs Market Size, By Region, 2023F (%)
Figure 36: North America Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 37: United States Spending on Medicines, 2013-2017 (In USD Billion)
Figure 38: Patented and Non-Patented Drugs Sales in Canada, 2013-2016 (USD Billion)
Figure 39: North America Diseases Outlook
Figure 40: United States health care expenditure per capita,2013-2016(USD)
Figure 41: Canada health care expenditure per capita,2013-2016(USD)
Figure 42: North America population aged 65 and above, 2013-2017 (% of total)
Figure 43: North America Healthcare Cost Per Capita, 2017 (USD)
Figure 44: North America GDP per Capita, 2013-2017 (USD)
Figure 45: North America Antifungal Drugs Market, By Value, 2018-2023 (USD Million)
Figure 46: North America Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 47: North America Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 48: North America Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 49: North America Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 50: North America Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 51: North America Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 52: North America Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 53: North America Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 54: North America Antifungal Drugs Market Size, By Countries, 2023F (%)
Figure 55: USA Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 56: USA Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 57: United States Fungal Infection Facts & Figures
Figure 58: New Patients Diagnosed with HIV in 2017, By Age Group
Figure 59: United States Per Capita Spending on Medicines, 2013-2017 (In USD)
Figure 60: Pharmacy & Drug Store Sales in United States, 2013-2016 (In USD Billion)
Figure 61: Medical and Healthcare Research & Development Spending, 2013-2016 (In USD Million)
Figure 62: U.S., Population ages 65 and above, 2013-2017 (% of total)
Figure 63: U.S., Population ages 65 and above, Forecast (In Millions)
Figure 64: U.S., Per Capita Expenditure on Healthcare, 2012-2018E (In USD)
Figure 65: U.S., GDP (Current USD), 2013-2017 (In USD Trillion)
Figure 66: USA Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 67: USA Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 68: USA Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 69: USA Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 70: USA Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 71: USA Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 72: USA Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 73: Leading Antifungal Drugs Companies In The United States of America
Figure 74: Canada Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 75: Canada Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 76: Estimated Number of Serious Fungal Infections Cases in Canada, 2014
Figure 77: Estimated Number of Mucosal Candidiasis in Canada, 2014
Figure 78: Estimated Number of Opportunistic Invasive Fungal Infections Cases in Canada, 2014
Figure 79: Estimated Number of Endemic Mycoses Cases in Canada, 2014
Figure 80: Estimated Number of Non-Invasive Pulmonary Aspergillosis Cases in Canada, 2014
Figure 81: Number of Retail Pharmacies in Canada, 2013-2017
Figure 82: Number of Hospitals Establishments in Canada, By Province, 2015
Figure 83: Number HIV Cases in Canada, 2013-2016
Figure 84: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %)
Figure 85: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
Figure 86: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
Figure 87: Canada Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 88: Canada Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 89: Canada Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 90: Canada Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 91: Canada Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 92: Canada Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 93: Canada Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 94: Leading Antifungal Drugs Companies In Canada
Figure 95: Europe Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 96: Europe Health Expenditure, By Select Country, 2016 (% of GDP)
Figure 97: Europe Population ages 65 years and above (% of total population), 2013-17
Figure 98: Europe, Fungal Infections Burden, (Per 100000 population), By Selected Countries
Figure 99: Europe Antifungal Drugs Market, By Value, 2018-2023 (USD Million)
Figure 100: Europe Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 101: Europe Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 102: Europe Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 103: Europe Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 104: Europe Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 105: Europe Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 106: Europe Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 107: Europe Antifungal Drugs Market Size, By Countries, 2017 (%)
Figure 108: Europe Antifungal Drugs Market Size, By Countries, 2023F (%)
Figure 109: Germany Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 110: Germany Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 111: Germany, Healthcare Related Statistics, 2017
Figure 112: Germany, Leukemia Incidences, 2014 & 2018E
Figure 113: Germany, Population ages 65 and above, 2012-2017 (% total)
Figure 114: Germany, Cause of Deaths, Percentage Change ,2007-2017
Figure 115: Germany, Cause of Deaths, Percentage Change ,2007-2017
Figure 116: Germany, HIV Prevalence, 2013-2017
Figure 117: Germany, Prevalence of Cancer, 2018 (% of total)
Figure 118: Germany Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 119: Germany Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 120: Germany Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 121: Germany Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 122: Germany Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 123: Germany Antifungal Drugs Market, By herapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 124: Germany Antifungal Drugs Market, By herapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 125: Leading Antifungal Drugs Companies In Germany
Figure 126: France Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 127: France Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 128: France, Healthcare Infrastructure Related Statistics
Figure 129: France, Health Expenditure, (% of GDP), 2012-2015 (USD)
Figure 130: France, Population Ages 65 and Above (% of total), 2012-2017
Figure 131: France, Prevalence of Cancer, 2018, (% of total)
Figure 132: France, Spending on Healthcare, 2015 & 2040$, (USD Per Person)
Figure 133: France Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 134: France Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 135: France Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 136: France Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 137: France Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 138: France Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 139: France Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 140: Leading Antifungal Drugs Companies In France
Figure 141: U.K Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 142: U.K Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 143: U.K, Health Expenditure, (% of GDP), 2013-2017 (USD)
Figure 144: U.K, Population Ages 65 and Above (% of total), 2012-2017
Figure 145: UK, Prevalence of Cancer, 2018, (% of Total)
Figure 146: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)
Figure 147: UK, Healthcare Infrastructure Related Statistics
Figure 148: Candidaemia per 100,000 population by region (England, Wales and Northern Ireland), 2013-2017
Figure 149: U.K Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 150: U.K Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 151: U.K Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 152: U.K Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 153: U.K Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 154: U.K Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 155: U.K Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 156: Leading Antifungal Drugs Companies In U.K
Figure 157: APAC Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 158: GDP Per Capita in APAC, By Select Country, 2016 (In USD)
Figure 159: Population ages 65 and above, By Select Country, 2017 (% of total)
Figure 160: Cancer Incidences in Asia, (% of Total), 2018
Figure 161: China, Pharmaceuticals Industry Revenue (USD Billion)
Figure 162: Japan, Total Drugs Market, 2013-2017, USD Billion
Figure 163: India Pharma Market, 2015-2017, (USD Billion)
Figure 164: APAC Antifungal Drugs Market, By Value, 2018-2023 (USD Million)
Figure 165: APAC Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 166: APAC Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 167: APAC Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 168: APAC Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 169: APAC Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 170: APAC Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 171: APAC Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 172: APAC Antifungal Drugs Market Size, By Countries, 2017 (%)
Figure 173: APAC Antifungal Drugs Market Size, By Countries, 2023F (%)
Figure 174: China Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 175: China Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 176: China, Fungal Infections Facts & Figures
Figure 177: China, Number of HIV Patients
Figure 178: China, Cancer Incidences ( in Million)
Figure 179: China, GDP Growth Per Year, 2015-2019 (In %)
Figure 180: China, Share of Urban Population, 2012-2017 (In %)
Figure 181: China, Total Population, 2013-2021F (In Billion)
Figure 182: China Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 183: China Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 184: China Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 185: China Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 186: China Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 187: China Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 188: China Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 189: Leading Antifungal Drugs Companies In China
Figure 190: Japan Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 191: Japan Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 192: Japan, Population ages 65 and above, 2012-2017 (% of total)
Figure 193: Japan, HIV Prevalence, 2017
Figure 194: Japan, Medical Facilities Outlook
Figure 195: Japan Healthcare Expenditure Outlook (%)
Figure 196: Japan, GDP Growth Per Year, 2015-2019F (In %)
Figure 197: Japan, Population ages 65 and above, 2012-2016 (% of total)
Figure 198: Japan Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 199: Japan Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 200: Japan Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 201: Japan Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 202: Japan Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 203: Japan Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 204: Japan Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023 (USD Million)
Figure 205: Leading Antifungal Drugs Companies In Japan
Figure 206: India Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 207: India Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 208: India, Fungal Infection Facts & Figures
Figure 209: India, Diseases & Medical Industry Outlook
Figure 210: India, Population ages 65 and above, 2013-2017
Figure 211: India, Total Population, 2013-2023F (In Billion)
Figure 212: Pharma Export From India Market, 2013-2017, (USD Billion)
Figure 213: India Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 214: India Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 215: India Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 216: India Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 217: India Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 218: India Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 219: India Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 220: Leading Antifungal Drugs Companies In India
Figure 221: ROW Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 222: Fungal Infection Burden in Latin America & Egypt, By Selected Countries
Figure 223: HIV Prevalence in LA&C and MENA (% of total), 2018
Figure 224: Cancer Prevalence in MENA (% of total), 2018
Figure 225: Cancer Prevalence in Latin America & Caribbean, (% of total), 2018
Figure 226: GDP Per Capita in ROW, By Select Country, 2013 (In USD)
Figure 227: GDP Per Capita in ROW, By Select Country, 2017 (In USD)
Figure 228: Latin America and Caribbean, Population ages 65 and above 2012-2017(% of total)
Figure 229: Middle East and North Africa, Population ages 65 and above (% of total)
Figure 230: ROW Antifungal Drugs Market, By Value, 2018-2023 (USD Million)
Figure 231: ROW Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 232: ROW Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 233: ROW Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 234: ROW Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 235: ROW Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 236: ROW Antifungal Drugs Market,By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 237: ROW Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 238: Branded Antifungal Drugs Sales, 2017, (USD Million)
Figure 239: Merck & Co., Revenues 2013-2017(USD Million)
Figure 240: Merck & Co., Revenues, By Region, 2017(% of Total)
Figure 241: Merck & Co., Revenues, By Region, 2017(% of Total)
Figure 242: Pfizer, Net Sales, 2013-2017 (USD Million)
Figure 243: Pfizer, Revenue, By Segments, 2017 (%)
Figure 244: Vfend, Net Sales, 2015-2017 (USD Million)
Figure 245: GSK, Revenues, 2013-2017 (USD Million)
Figure 246: GSK, Revenue, By Region, 2017 (USD Million)
Figure 247: GSK, Revenue, By Segments, 2017(%)
Figure 248: GSK, Revenue, By Pharmaceuticals Segment, 2017 (USD Million)
Figure 249: Novartis, Net Sales, 2013-2017 (USD Million)
Figure 250: Novartis, Revenue, By Segment, 2017(%)
Figure 251: Novartis, Revenue, By Region, 2017(%)
Figure 252: Abbott Laboratories, Net Sales, 2013-2017 (USD Million)
Figure 253: bbott Laboratories, Revenue, By Segments, 2017(%)
Figure 254: Abbott Laboratories, Revenue, By Regions, 2017(%)
Figure 255: Astellas, Net Sales, 2013-2017 (USD Million)
Figure 256: Astellas, Revenue, By Regions, 2017(%)
Figure 257: Astellas, Revenue, By Segments, 2017(%)
Figure 258: Bayer, Net Sales, 2013-2017 (USD Million)
Figure 259: Bayer, Net Sales, 2013-2017 (USD Million)
Figure 260: Bayer, Revenue, By Segments, 2017(%)
Figure 261: Sanofi, Net Sales, 2013-2017 (USD Million)
Figure 262: Bio-Rad Revenue, By Region, 2017(%)
LIST OF TABLEs
Table 1: Different Types of Common Fungal Diseases
Table 2: Different Class of Anti-Fungal Drugs
Table 3: Common Invasive Fungal Diseases and Their Treatment Options
Table 4: Common Invasive Fungal Diseases and Their Treatment Options
Table 5: Burden of Fungal Diseases
Table 6: Antifungal Compounds in Development Stage – By Phases
Table 7: EU-5 Socio-Economical Statistics, 2017
Table 8: Germany, Fungal Infection Burden
Table 9: France, Fungal Infection Burden
Table 10: Invasive Fungal Infection Burden In UK
Table 11: Estimated Antifungal Prevalence in Japan, 2016
Table 12: Percentage aged 60 years and over, (2000, 2015, 2030,2050)
Table 13: Competitive Landscape - Leading Companies – Sales by Drug Class
Figure 1: Global Antifungal Drugs Market Size, By Value, 2013-2017 (USD Million)
Figure 2: Number of People Living With HIV, 2013-2017
Figure 3: Number of New Cases of Cancer, In 2018, By Type, (% of Total)
Figure 4: Estimated TB Incidences, By WHO Regions, 2016
Figure 5: Prevalence of Diagnosed Autoimmune Diseases, In 2018, By Selected Countries, (% of Total)
Figure 6: Burden of Antifungal Infections, By Type
Figure 7: Generic Market Value Share, In 2006 (Left) &2016 (Right), By Region
Figure 8: Global Prescription and OTC Drugs Sales, 2013-2017, (USD Billion)
Figure 9: Expected Global Medical Spending in 2020, By Product Type, (% of Total)
Figure 10: Expected Global Medical Spending in 2020, By Region, (% of Total)
Figure 11: Global Aged Population (Above 65), 2013-2017 (% of total)
Figure 12: Global Aged Population(Above 65), By Country, 2017 (% of total)
Figure 13: Healthcare Expenditure (Share of GDP), By Selected Country, 2013-2017 (In %)
Figure 14: GDP Per Capita PPP, By Region, 2018 (in Thousand USD)
Figure 15: Global Expected Healthcare Industry Outlook
Figure 16: Regional Expected Healthcare Industry Growth Rate By Year 2020
Figure 17: Global Antifungal Drugs Market Size, By Value, Forecast, 2018-2023 (USD Million)
Figure 18: Global Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 19: Global Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 20: Global Azoles Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 21: Global Azoles Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 22: Global Echinocandins Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 23: Global Echinocandins Antifungal Drugs Market, 2018-2023(USD Million)
Figure 24: Global Polyenes Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 25: Global Polyenes Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 26: Global Other Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 27: Global Other Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 28: Market Comparison Chart, By Product Type, 2013-2023 (USD Million)
Figure 29: Global Market Attractiveness, By Product Type, 2023F
Figure 30: Global Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 31: Global Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 32: Global Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 33: Global Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 34: Global Antifungal Drugs Market Size, By Region, 2017 (%)
Figure 35: Global Antifungal Drugs Market Size, By Region, 2023F (%)
Figure 36: North America Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 37: United States Spending on Medicines, 2013-2017 (In USD Billion)
Figure 38: Patented and Non-Patented Drugs Sales in Canada, 2013-2016 (USD Billion)
Figure 39: North America Diseases Outlook
Figure 40: United States health care expenditure per capita,2013-2016(USD)
Figure 41: Canada health care expenditure per capita,2013-2016(USD)
Figure 42: North America population aged 65 and above, 2013-2017 (% of total)
Figure 43: North America Healthcare Cost Per Capita, 2017 (USD)
Figure 44: North America GDP per Capita, 2013-2017 (USD)
Figure 45: North America Antifungal Drugs Market, By Value, 2018-2023 (USD Million)
Figure 46: North America Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 47: North America Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 48: North America Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 49: North America Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 50: North America Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 51: North America Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 52: North America Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 53: North America Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 54: North America Antifungal Drugs Market Size, By Countries, 2023F (%)
Figure 55: USA Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 56: USA Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 57: United States Fungal Infection Facts & Figures
Figure 58: New Patients Diagnosed with HIV in 2017, By Age Group
Figure 59: United States Per Capita Spending on Medicines, 2013-2017 (In USD)
Figure 60: Pharmacy & Drug Store Sales in United States, 2013-2016 (In USD Billion)
Figure 61: Medical and Healthcare Research & Development Spending, 2013-2016 (In USD Million)
Figure 62: U.S., Population ages 65 and above, 2013-2017 (% of total)
Figure 63: U.S., Population ages 65 and above, Forecast (In Millions)
Figure 64: U.S., Per Capita Expenditure on Healthcare, 2012-2018E (In USD)
Figure 65: U.S., GDP (Current USD), 2013-2017 (In USD Trillion)
Figure 66: USA Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 67: USA Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 68: USA Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 69: USA Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 70: USA Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 71: USA Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 72: USA Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 73: Leading Antifungal Drugs Companies In The United States of America
Figure 74: Canada Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 75: Canada Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 76: Estimated Number of Serious Fungal Infections Cases in Canada, 2014
Figure 77: Estimated Number of Mucosal Candidiasis in Canada, 2014
Figure 78: Estimated Number of Opportunistic Invasive Fungal Infections Cases in Canada, 2014
Figure 79: Estimated Number of Endemic Mycoses Cases in Canada, 2014
Figure 80: Estimated Number of Non-Invasive Pulmonary Aspergillosis Cases in Canada, 2014
Figure 81: Number of Retail Pharmacies in Canada, 2013-2017
Figure 82: Number of Hospitals Establishments in Canada, By Province, 2015
Figure 83: Number HIV Cases in Canada, 2013-2016
Figure 84: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %)
Figure 85: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
Figure 86: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
Figure 87: Canada Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 88: Canada Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 89: Canada Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 90: Canada Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 91: Canada Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 92: Canada Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 93: Canada Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 94: Leading Antifungal Drugs Companies In Canada
Figure 95: Europe Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 96: Europe Health Expenditure, By Select Country, 2016 (% of GDP)
Figure 97: Europe Population ages 65 years and above (% of total population), 2013-17
Figure 98: Europe, Fungal Infections Burden, (Per 100000 population), By Selected Countries
Figure 99: Europe Antifungal Drugs Market, By Value, 2018-2023 (USD Million)
Figure 100: Europe Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 101: Europe Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 102: Europe Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 103: Europe Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 104: Europe Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 105: Europe Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 106: Europe Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 107: Europe Antifungal Drugs Market Size, By Countries, 2017 (%)
Figure 108: Europe Antifungal Drugs Market Size, By Countries, 2023F (%)
Figure 109: Germany Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 110: Germany Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 111: Germany, Healthcare Related Statistics, 2017
Figure 112: Germany, Leukemia Incidences, 2014 & 2018E
Figure 113: Germany, Population ages 65 and above, 2012-2017 (% total)
Figure 114: Germany, Cause of Deaths, Percentage Change ,2007-2017
Figure 115: Germany, Cause of Deaths, Percentage Change ,2007-2017
Figure 116: Germany, HIV Prevalence, 2013-2017
Figure 117: Germany, Prevalence of Cancer, 2018 (% of total)
Figure 118: Germany Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 119: Germany Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 120: Germany Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 121: Germany Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 122: Germany Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 123: Germany Antifungal Drugs Market, By herapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 124: Germany Antifungal Drugs Market, By herapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 125: Leading Antifungal Drugs Companies In Germany
Figure 126: France Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 127: France Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 128: France, Healthcare Infrastructure Related Statistics
Figure 129: France, Health Expenditure, (% of GDP), 2012-2015 (USD)
Figure 130: France, Population Ages 65 and Above (% of total), 2012-2017
Figure 131: France, Prevalence of Cancer, 2018, (% of total)
Figure 132: France, Spending on Healthcare, 2015 & 2040$, (USD Per Person)
Figure 133: France Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 134: France Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 135: France Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 136: France Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 137: France Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 138: France Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 139: France Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 140: Leading Antifungal Drugs Companies In France
Figure 141: U.K Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 142: U.K Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 143: U.K, Health Expenditure, (% of GDP), 2013-2017 (USD)
Figure 144: U.K, Population Ages 65 and Above (% of total), 2012-2017
Figure 145: UK, Prevalence of Cancer, 2018, (% of Total)
Figure 146: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)
Figure 147: UK, Healthcare Infrastructure Related Statistics
Figure 148: Candidaemia per 100,000 population by region (England, Wales and Northern Ireland), 2013-2017
Figure 149: U.K Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 150: U.K Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 151: U.K Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 152: U.K Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 153: U.K Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 154: U.K Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 155: U.K Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 156: Leading Antifungal Drugs Companies In U.K
Figure 157: APAC Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 158: GDP Per Capita in APAC, By Select Country, 2016 (In USD)
Figure 159: Population ages 65 and above, By Select Country, 2017 (% of total)
Figure 160: Cancer Incidences in Asia, (% of Total), 2018
Figure 161: China, Pharmaceuticals Industry Revenue (USD Billion)
Figure 162: Japan, Total Drugs Market, 2013-2017, USD Billion
Figure 163: India Pharma Market, 2015-2017, (USD Billion)
Figure 164: APAC Antifungal Drugs Market, By Value, 2018-2023 (USD Million)
Figure 165: APAC Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 166: APAC Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 167: APAC Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 168: APAC Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 169: APAC Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 170: APAC Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 171: APAC Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 172: APAC Antifungal Drugs Market Size, By Countries, 2017 (%)
Figure 173: APAC Antifungal Drugs Market Size, By Countries, 2023F (%)
Figure 174: China Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 175: China Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 176: China, Fungal Infections Facts & Figures
Figure 177: China, Number of HIV Patients
Figure 178: China, Cancer Incidences ( in Million)
Figure 179: China, GDP Growth Per Year, 2015-2019 (In %)
Figure 180: China, Share of Urban Population, 2012-2017 (In %)
Figure 181: China, Total Population, 2013-2021F (In Billion)
Figure 182: China Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 183: China Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 184: China Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 185: China Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 186: China Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 187: China Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 188: China Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 189: Leading Antifungal Drugs Companies In China
Figure 190: Japan Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 191: Japan Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 192: Japan, Population ages 65 and above, 2012-2017 (% of total)
Figure 193: Japan, HIV Prevalence, 2017
Figure 194: Japan, Medical Facilities Outlook
Figure 195: Japan Healthcare Expenditure Outlook (%)
Figure 196: Japan, GDP Growth Per Year, 2015-2019F (In %)
Figure 197: Japan, Population ages 65 and above, 2012-2016 (% of total)
Figure 198: Japan Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 199: Japan Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 200: Japan Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 201: Japan Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 202: Japan Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 203: Japan Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 204: Japan Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023 (USD Million)
Figure 205: Leading Antifungal Drugs Companies In Japan
Figure 206: India Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 207: India Antifungal Drugs Market, By Value, 2018-2023(USD Million)
Figure 208: India, Fungal Infection Facts & Figures
Figure 209: India, Diseases & Medical Industry Outlook
Figure 210: India, Population ages 65 and above, 2013-2017
Figure 211: India, Total Population, 2013-2023F (In Billion)
Figure 212: Pharma Export From India Market, 2013-2017, (USD Billion)
Figure 213: India Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 214: India Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 215: India Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 216: India Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 217: India Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 218: India Antifungal Drugs Market, By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 219: India Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 220: Leading Antifungal Drugs Companies In India
Figure 221: ROW Antifungal Drugs Market, By Value, 2013-2017 (USD Million)
Figure 222: Fungal Infection Burden in Latin America & Egypt, By Selected Countries
Figure 223: HIV Prevalence in LA&C and MENA (% of total), 2018
Figure 224: Cancer Prevalence in MENA (% of total), 2018
Figure 225: Cancer Prevalence in Latin America & Caribbean, (% of total), 2018
Figure 226: GDP Per Capita in ROW, By Select Country, 2013 (In USD)
Figure 227: GDP Per Capita in ROW, By Select Country, 2017 (In USD)
Figure 228: Latin America and Caribbean, Population ages 65 and above 2012-2017(% of total)
Figure 229: Middle East and North Africa, Population ages 65 and above (% of total)
Figure 230: ROW Antifungal Drugs Market, By Value, 2018-2023 (USD Million)
Figure 231: ROW Antifungal Drugs Market Size, By Drug Class, 2017 (%)
Figure 232: ROW Antifungal Drugs Market Size, By Drug Class, 2023F (%)
Figure 233: ROW Antifungal Drugs Market, By Drug Class, By Value, 2013-2017 (USD Million)
Figure 234: ROW Antifungal Drugs Market Size, By Therapeutic Indications, 2017 (%)
Figure 235: ROW Antifungal Drugs Market Size, By Therapeutic Indications, 2023F (%)
Figure 236: ROW Antifungal Drugs Market,By Therapeutic Indications, By Value, 2013-2017 (USD Million)
Figure 237: ROW Antifungal Drugs Market, By Therapeutic Indications, By Value, 2018-2023(USD Million)
Figure 238: Branded Antifungal Drugs Sales, 2017, (USD Million)
Figure 239: Merck & Co., Revenues 2013-2017(USD Million)
Figure 240: Merck & Co., Revenues, By Region, 2017(% of Total)
Figure 241: Merck & Co., Revenues, By Region, 2017(% of Total)
Figure 242: Pfizer, Net Sales, 2013-2017 (USD Million)
Figure 243: Pfizer, Revenue, By Segments, 2017 (%)
Figure 244: Vfend, Net Sales, 2015-2017 (USD Million)
Figure 245: GSK, Revenues, 2013-2017 (USD Million)
Figure 246: GSK, Revenue, By Region, 2017 (USD Million)
Figure 247: GSK, Revenue, By Segments, 2017(%)
Figure 248: GSK, Revenue, By Pharmaceuticals Segment, 2017 (USD Million)
Figure 249: Novartis, Net Sales, 2013-2017 (USD Million)
Figure 250: Novartis, Revenue, By Segment, 2017(%)
Figure 251: Novartis, Revenue, By Region, 2017(%)
Figure 252: Abbott Laboratories, Net Sales, 2013-2017 (USD Million)
Figure 253: bbott Laboratories, Revenue, By Segments, 2017(%)
Figure 254: Abbott Laboratories, Revenue, By Regions, 2017(%)
Figure 255: Astellas, Net Sales, 2013-2017 (USD Million)
Figure 256: Astellas, Revenue, By Regions, 2017(%)
Figure 257: Astellas, Revenue, By Segments, 2017(%)
Figure 258: Bayer, Net Sales, 2013-2017 (USD Million)
Figure 259: Bayer, Net Sales, 2013-2017 (USD Million)
Figure 260: Bayer, Revenue, By Segments, 2017(%)
Figure 261: Sanofi, Net Sales, 2013-2017 (USD Million)
Figure 262: Bio-Rad Revenue, By Region, 2017(%)
LIST OF TABLEs
Table 1: Different Types of Common Fungal Diseases
Table 2: Different Class of Anti-Fungal Drugs
Table 3: Common Invasive Fungal Diseases and Their Treatment Options
Table 4: Common Invasive Fungal Diseases and Their Treatment Options
Table 5: Burden of Fungal Diseases
Table 6: Antifungal Compounds in Development Stage – By Phases
Table 7: EU-5 Socio-Economical Statistics, 2017
Table 8: Germany, Fungal Infection Burden
Table 9: France, Fungal Infection Burden
Table 10: Invasive Fungal Infection Burden In UK
Table 11: Estimated Antifungal Prevalence in Japan, 2016
Table 12: Percentage aged 60 years and over, (2000, 2015, 2030,2050)
Table 13: Competitive Landscape - Leading Companies – Sales by Drug Class
